Assessment, Self, Copd, Hospitalization
Conditions
Brief summary
To evaluate whether a digital support and communication platform for COPD patients after 6 months provides: 1. Decreased breathlessness on the basis of modified medical research council dyspnea scale \[mMRC\] 2. Improved health status and symptom relief based on COPD assessment scale \[CAT\] 3. Improved quality of life based on EQ-5D 4. Reduction in the number of incidents, hospital nights, the number of hospitalizations, outpatient contacts or the number of deaths related to COPD 5. A change in the classification of COPD severity based on GOLD A-D
Interventions
DEVICELifePod
LifePod consists of a Web-based E-Health platform with two interfaces, one medical for healthcare professionals and one patient interface. LifePod is accessed via a smartphone, tablets and computers via a web application where patients enter symptom parameters and vital parameters such as breathing and mucus status, weight, activity, medication or other disease-specific values. Several different validated questionnaires are sent regularly to the patient to obtain information about the patient's mood and activity. The platform contains a chat function between healthcare professionals and patients. A unique health profile is created in which the patient self-reports their health. The patient receives direct feedback in their web application if they are within the interval given for the individual. The medical interfaces are designed so that patients are automatically placed in a priority order where the person outside the given range is given top priority.
Sponsors
Lund University
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
The patient is included in the study in connection with visits to COPD. * Diagnosed COPD J44 (newly discovered or existing) * Have completed the consent form * Is judged to be able to handle the intervention himself or with the help of staff or relatives
Exclusion criteria
Patient who declines to participate in the trial. * Impaired cognitive ability that is judged to affect the ability to conduct the study in the intended manner. * Life expectancy \<8 months * In other ways, treating physicians are deemed to be inappropriate to participate in the study, e.g. due to participation in another study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severity of dyspnea on the basis of modified medical research council dyspnea scale [mMRC] | 6 months | Dyspnea is measured with mMRC from 0-4 where high figure represent dyspnea in minimal exertion |
| Change in health status and symptom relief based on COPD assessment scale [CAT] | 6 months | Health status and symptom is evaluated with COPD assessment scale (CAT) where the scale is from 0-40 and where high score represent worse health status and symptoms |
| Change in quality of life | 6 months | Improved quality of life as measured on visual analogue scale 0-100 where high figure represent best quality of life |
| A change in the classification of COPD severity based on GOLD A-D | 6 months | A change in the classification of COPD severity based on GOLD 1-4 (A-D) where high figure represent worse severity |
| Change in patient reported symptoms | 6 months | Improved patient-reported symptoms as measured by questionnaire EuroQol three-dimensional questionnaire (EQ-5D-3L ) where high score represent worse symptoms. The minimum score is 7 points and the maximum score is 23 points. |
| Number of participants with COPD related events and deaths during intervention and up to 12 months after inclusion | 12 months | — |
| Number of participants with new hospitalization up 12 months after inclusion | 12 months | — |
| Number of hospital days during intervention and up 12 months after inclusion | 12 months | — |
| Number of health care visits during intervention and up to 12 months after inclusion | 12 months | — |
Countries
Sweden
Outcome results
None listed